The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers

Authors:

Moh’d Khushman, Sharon Wu, Joanne Xiu, Alex Farrell, Anthony Shields, John Marshall, Heinz-Josef Lenz, Michael Hall, Jim Abraham, Matthew Oberley, George Sledge, David Spetzler, Ibrahim Sahin, Michael Iglesia, Emil Lou

Introduction

  • In patients with mismatch repair deficient (dMMR) colorectal cancers (CRCs), we previously reported that loss of expression of MSH2 and MSH6 (MutS co-loss) was associated with better response to ICIs and longer median overall survival (mOS) compared to loss of expression of MLH1 and PMS2 (MutL co-loss).
  • Here, we expanded our analysis and included gastrointestinal (GI) non-CRCs and explored the impact of dual vs. monotherapy ICIs on mOS in GI (CRC and non-CRC) cancers.
Download Publication